References
- Wurz GT, Kao C-J, DeGregorio MW. Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Ther Adv Med Oncol [Internet]. 2016 [cited 2017 Dec 7];8:4–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26753003 doi:10.1177/1758834015615514.
- Inman BA, Longo TA, Ramalingam S, Harrison MR. Atezolizumab: a PD-L1 blocking antibody for bladder cancer. Clin Cancer Res. 2017;23(8):1886–1890. doi:10.1158/1078-0432.CCR-16-1417.
- Jung K, Zeng X, Bilusic M. Nivolumab-associated acute glomerulonephritis: a case report and literature review. BMC Nephrol [Internet]. 2016;17:188. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27876011 doi:10.1186/s12882-016-0408-2.
- Escandon J, Peacock S, Trabolsi A, Thomas DB, Layka A, Lutzky J. Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor. J Immunother cancer [Internet]. 2017;5:3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28105370 doi:10.1186/s40425-016-0205-2.
- Hahn AW, Gill DM, Agarwal N, Maughan BL. PD-1 checkpoint inhibition: Toxicities and management. Urol Oncol. 2017;35(12):701/707. doi:10.1016/j.urolonc.2017.08.005.
- Wanchoo R, Karam S, Uppal NN, Barta VS, Deray G, Devoe C, Launay-Vacher V, Jhaveri KD. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. Am J Nephrol. 2017;45:160–9. doi:10.1159/000455014. PMID:28076863.
- Institute NC. Common Terminology Criteria for Adverse Events (CTCAE) [Internet]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-%0A06-14_QuickReference_8.5x11.pdf
- Deng R, Bumbaca D, Pastuskovas CV, Boswell CA, West D, Cowan KJ, Chiu H, McBride J, Johnson C, Xin Y, et al. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. MAbs. 2016;8:593–603. doi:10.1080/19420862.2015.1136043. PMID:26918260.
- Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albiges L, Bellmunt J, Song J, Carvo I, Lampron M, et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol Off J Eur Soc Med Oncol [Internet]. 2014;25:2178–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25193987 doi:10.1093/annonc/mdu445.
- Hagerty DT, Allen PM. Processing and presentation of self and foreign antigens by the renal proximal tubule. J Immunol [Internet]. 1992 [cited 2017 Dec 7];148:2324–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1560195
- Schoop R. Suppressed T-cell activation by IFN- -induced expression of PD-L1 on renal tubular epithelial cells. Nephrol Dial Transplant [Internet]. 2004;19:2713–20. Available from: https://academic.oup.com/ndt/article-lookup/doi/10.1093/ndt/gfh423 doi:10.1093/ndt/gfh423.
- Ding H, Wu X, Gao W. PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis. Clin Immunol. 2005;115:184–91. doi:10.1016/j.clim.2005.01.005. PMID:15885642.
- Menke J, Lucas JA, Zeller GC, Mary E, Huang XR, Tsuboi N, Mayadas TN, Lan HY, Sharpe AH, Kelley VR. Programmed Death 1 Ligand (PD-L) 1 and PD-L2 Limit Autoimmune Kidney Disease: Distinct Roles. J Immunol. 2007;179:7466–77. doi:10.4049/jimmunol.179.11.7466. PMID:18025191.
- Uchida A, Watanabe M, Nawata A, Ikari Y, Sasaki M, Shigemoto K, Hisano S, Nakashima H. Tubulointerstitial nephritis as adverse effect of programmed cell death 1 inhibitor, nivolumab, showed distinct histological findings. CEN Case Rep. 2017;6(2):169–174. doi:10.1007/s13730-017-0269-y.
- Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng S, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature [Internet]. 2014 [cited 2017 Dec 7];515:558–62. Available from: http://www.nature.com/doifinder/10.1038/nature13904 doi:10.1038/nature13904.
- Spanou Z. Involvement of Drug-Specific T Cells in Acute Drug-Induced Interstitial Nephritis. J Am Soc Nephrol [Internet]. 2006;17:2919–27. Available from: http://www.jasn.org/cgi/doi/10.1681/ASN.2006050418 doi:10.1681/ASN.2006050418.
- Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, Le DT, Lipson EJ, Glezerman IG, Wolchok J, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int [Internet]. 2016;90:638–47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27282937 doi:10.1016/j.kint.2016.04.008.
- Shirali AC, Perazella MA, Gettinger S. Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. Am J Kidney Dis [Internet]. 2016 [cited 2017 Dec 7];68:287–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27113507 doi:10.1053/j.ajkd.2016.02.057.
- Izzedine H, Mateus C, Boutros C, Robert C, Rouvier P, Amoura Z, Mathian A. Renal effects of immune checkpoint inhibitors. Nephrol Dial Transplant [Internet]. 2016;4:gfw382. Available from: https://academic.oup.com/ndt/article-lookup/doi/10.1093/ndt/gfw382 doi:10.1093/ndt/gfw382.
- Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, Hernandez G, Mier J, He X, Hodi FS, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016;7:1–8. doi:10.1038/ncomms12624.
- Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet A-L, Latreche S, Bergaya S, Benhamouda N, Tanchot C, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med [Internet]. 2015;212:139–48. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25601652 doi:10.1084/jem.20140559.
- Li Y-L, Zhao H, Ren X-B, Li Y-L, Zhao H, Ren X-B. Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward? Cancer Biol Med [Internet]. 2016 [cited 2017 Dec 7];13:206–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27458528 doi:10.20892/j.issn.2095-3941.2015.0070.
- Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol [Internet]. 2012;12:253–68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22437938 doi:10.1038/nri3175.
- Subramanian P, Haas NB. Recent advances in localized RCC: A focus on VEGF and immuno-oncology therapies. Urol Oncol Semin Orig Investig [Internet]. 2017;36:23–30. Available from: https://doi.org/10.1016/j.urolonc.2017.09.008 doi:10.1016/j.urolonc.2017.09.008.
- Barakat RK, Singh N, Lal R, Verani RR, Finkel KW, Foringer JR. Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma. Ann Pharmacother [Internet]. 2007 [cited 2017 Dec 7];41:707–10. Available from: http://journals.sagepub.com/doi/10.1345/aph.1H635 doi:10.1345/aph.1H635.
- Lomax AJ, Hill PA, Ashley DM. Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme. J Oncol Pharm Pract [Internet]. 2013 [cited 2017 Dec 7];19:365–8. Available from: http://journals.sagepub.com/doi/10.1177/1078155212466421 doi:10.1177/1078155212466421.
- Gurevich F, Perazella MA. Renal Effects of Anti-angiogenesis Therapy: Update for the Internist. Am J Med [Internet]. 2009;122:322–8. Available from: https://doi.org/10.1016/j.amjmed.2008.11.025 doi:10.1016/j.amjmed.2008.11.025.
- Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol [Internet]. 2006;24:2283–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16710025 doi:10.1200/JCO.2005.04.5716.
- Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res [Internet]. 2007;13:6681–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17982122 doi:10.1158/1078-0432.CCR-07-0187.
- Ascierto PA, Simeone E, Sileni VC, Pigozzo J, Maio M, Altomonte M, Del Vecchio M, Di Guardo L, Marchetti P, Ridolfi R, et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med [Internet]. 2014;12:116. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24885479 doi:10.1186/1479-5876-12-116.
- Horvat TZ, Adel NG, Dang T-O, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo KM, et al. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol [Internet]. 2015;33:3193–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26282644 doi:10.1200/JCO.2015.60.8448.
- Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, Viollet R, Thomas M, Roy S, Benannoune N, et al. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. JAMA dermatology [Internet]. 2016;152:45–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26501224 doi:10.1001/jamadermatol.2015.2707.
- Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, Lin K, Quaglino P, Rappersberger K, Ortiz-Urda S. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA dermatology [Internet]. 2015;151:1206–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26222619 doi:10.1001/jamadermatol.2015.1916.
- Teulings H-E, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, Luiten RM. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol [Internet]. 2015;33:773–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25605840 doi:10.1200/JCO.2014.57.4756.
- Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clin Cancer Res [Internet]. 2016;22:886–94. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26446948 doi:10.1158/1078-0432.CCR-15-1136.
- Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, Sznol M, Long GV, Li H, Waxman IM, et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol [Internet]. 2017;35:785–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28068177 doi:10.1200/JCO.2015.66.1389.
- Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ, Li SW, Liu N, Yan CX. Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: A meta-analysis. Front Pharmacol. 2017;8:1–12. doi:10.3389/fphar.2017.00730. PMID:28149278.